Glucocorticoid regulation of inflammation and its functional correlates: From HPA axis to glucocorticoid receptor dysfunction

Annals of the New York Academy of Sciences

Volumn 1261, Issue 1, 2012, Pages 55-63

  Silverman, Marni N ^a   Sternberg, Esther M ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Autoimmune; Cortisol; Cytokines; Depression; Psychoneuroimmunology; Stress

Indexed keywords

BIOLOGICAL MARKER; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCORTIN;

ANEMIA; AUTOIMMUNE DISEASE; AUTONOMIC NEUROPATHY; BINDING AFFINITY; CARDIOVASCULAR DISEASE; CHRONIC FATIGUE SYNDROME; CHRONIC STRESS; COLITIS; CROHN DISEASE; DEPRESSION; ENDOCRINE DISEASE; ENTERITIS; ENVIRONMENTAL FACTOR; EPIGENETICS; FIBROMYALGIA; HEART RATE VARIABILITY; HEREDITY; HORMONE SYNTHESIS; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCORTISOLISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; ILLNESS BEHAVIOR; IMMUNOCOMPETENT CELL; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; METABOLIC SYNDROME X; MULTIPLE SCLEROSIS; NEGATIVE FEEDBACK; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; POINT MUTATION; POSTTRAUMATIC STRESS DISORDER; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PSYCHOPHYSIOLOGY; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; STRESS;

EID: 84864083173     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06633.x     Document Type: Review

References (98)

1. Sapolsky, R.M., L.M. Romero & A.U. Munck. 2000. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr. Rev. 21: 55-89.
2. Besedovsky, H.O. & A. del Rey. 1996. Immune-neuro-endocrine interactions: facts and hypotheses. Endocr. Rev. 17: 64-102.
3. McEwen, B.S. et al. 1997. The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. Brain Res. Brain Res. Rev. 23: 79-133.
4. Webster, J.I. & E.M. Sternberg. 2004. Role of the hypothalamic-pituitary-adrenal axis, glucocorticoids and glucocorticoid receptors in toxic sequelae of exposure to bacterial and viral products. J. Endocrinol. 181: 207-221.
5. Glezer, I. & S. Rivest. 2004. Glucocorticoids: protectors of the brain during innate immune responses. Neuroscientist 10: 538-552.
6. Sternberg, E.M. et al. 1989a. Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis- susceptible Lewis rats. Proc. Natl. Acad. Sci. U.S.A. 86: 2374-2378.
7. Crofford, L.J. 2002. The hypothalamic-pituitary-adrenal axis in the pathogenesis of rheumatic diseases. Endocrinol. Metab. Clin. North Am. 31: 1-13.
8. Chikanza, I.C., W. Kuis & C.J. Heijnen. 2000. The influence of the hormonal system on pediatric rheumatic diseases. Rheum. Dis. Clin. North Am. 26: 911-925.
9. Straub, R.H. et al. 2005. How psychological stress via hormones and nerve fibers may exacerbate rheumatoid arthritis. Arthritis Rheum. 52: 16-26.
10. Silverman, M.N. & E.M. Sternberg. 2008. Neuroendocrine-immune interactions in rheumatoid arthritis: mechanisms of glucocorticoid resistance. Neuroimmunomodulation 15: 19-28.
11. Stasi, C. & E. Orlandelli. 2008. Role of the brain-gut axis in the pathophysiology of Crohn's disease. Dig. Dis. 26: 156-166.
12. Mawdsley, J.E. & D.S. Rampton. 2005. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut 54: 1481-1491.
13. Gold, S.M. et al. 2005. The role of stress-response systems for the pathogenesis and progression of MS. Trends Immunol. 26: 644-652.
14. Buske-Kirschbaum, A. 2009. Cortisol responses to stress in allergic children: interaction with the immune response. Neuroimmunomodulation 16: 325-332.
15. Adcock, I.M. et al. 2008. Steroid resistance in asthma: mechanisms and treatment options. Curr. Allergy Asthma Rep. 8: 171-178.
16. Parker, A.J., S. Wessely & A.J. Cleare. 2001. The neuroendocrinology of chronic fatigue syndrome and fibromyalgia. Psychol. Med. 31: 1331-1345.
17. Neeck, G. & L.J. Crofford. 2000. Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome. Rheum. Dis. Clin. North Am. 26: 989-1002.
18. Silverman, M.N. et al. 2010. Neuroendocrine and immune contributors to fatigue. Physical Med. Rehab. 2: 338-346.
19. Holsboer, F. 2000. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23: 477-501.
20. Heim, C., U. Ehlert & D.H. Hellhammer. 2000. The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. Psychoneuroendocrinology 25: 1-35.
21. Raison, C.L. & A.H. Miller. 2003. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am. J. Psychiatry 160: 1554-1565.
22. Yehuda, R. 2009. Status of glucocorticoid alterations in post-traumatic stress disorder. Ann. N.Y. Acad. Sci. 1179: 56-69.
23. Anacker, C. et al. 2011. The glucocorticoid receptor: pivot of depression and of antidepressant treatment? Psychoneuroendocrinology 36: 415-425.
24. Pollak, Y. & R. Yirmiya. 2002. Cytokine-induced changes in mood and behaviour: implications for 'depression due to a general medical condition', immunotherapy and antidepressive treatment. Int. J. Neuropsychopharmacol. 5: 389-399.
25. Maes, M. 2008. Inflammatory and oxidative and nitrostative stress pathways underpinning chronic fatigue, somatization and psychosomatic symptoms. Curr. Opin. Psychiatry 22: 75-83.
26. Maes, M. et al. 2009. The inflammatory and neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab. Brain Dis. 24: 27-53.
27. Raison, C.L., L. Capuron & A.H. Miller. 2006. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 27: 24-31.
28. Dantzer, R. et al. 2008. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9: 46-57.
29. Loftis, J.M., M. Huckans & M.J. Morasco. 2010. Neuroimmne mechanisms of cytokine-induced depression: current theories and novel treatment strategies. Neurobiol. Dis. 37: 519-533.
30. Pace, T.W. & C.M. Heim. 2011. A short review on the psychoneuroimmunology of posttraumatic stress disorder: from risk factors to medical comorbidities. Brain Behav. Immun. 25: 6-13.
31. Gill, J.M. et al. 2009. PTSD is associated with an excess of inflammatory immune activities. Perspect. Psychiatr. Care 45: 262-277.
32. Gur, A. & P. Oktayoglu. 2008. Status of immune mediators in fibromyalgia. Curr. Pain Headache Rep. 12: 175-181.
33. Sternberg, E.M. et al. 1989b. A central nervous system defect in biosynthesis of corticotropin-releasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats. Proc. Natl. Acad. Sci. U.S.A. 86: 4771-4775.
34. Zelazowski, P. et al. 1993. Release of hypothalamic corticotropin-releasing hormone and arginine-vasopressin by interleukin 1 beta and alpha MSH: studies in rats with different susceptibility to inflammatory disease. Brain Res. 631: 22-26.
35. Calogero, A.E. et al. 1992. Neurotransmitter-induced hypothalamic-pituitary-adrenal axis responsiveness is defective in inflammatory disease-susceptible Lewis rats: in vivo and in vitro studies suggesting globally defective hypothalamic secretion of corticotropin-releasing hormone. Neuroendocrinology 55: 600-608.
36. Zelazowski, P. et al. 1992. In vitro regulation of pituitary ACTH secretion in inflammatory disease susceptible Lewis (LEW/N) and inflammatory disease resistant Fischer (F344/N) rats. Neuroendocrinology 56: 474-482.
37. Bernardini, R. et al. 1996. Adenylate-cyclase-dependent pituitary adrenocorticotropin secretion is defective in the inflammatory-disease-susceptible Lewis rat. Neuroendocrinology 63: 468-474.
38. Barnes, P.J. 2006. Corticosteroid effects on cell signalling. Eur. Respir J. 27: 413-426.
39. De Bosscher, K., W. Vanden Berghe & G. Haegeman. 2006. Cross-talk between nuclear receptors and nuclear factor kappaB. Oncogene 25: 6868-6886.
40. van Rossum, E.F. & E.L. van den Akker. 2010. Glucocorticoid resistance. Endocr. Dev. 20: 127-136.
41. Manenschijn, L. et al. 2009. Clinical features associated with glucocorticoid receptor polymorphisms. An overview. Ann. N.Y. Acad. Sci. 1179: 179-198.
42. DeRijk, R. & E.R. de Kloet. 2005. Corticosteroid receptor genetic polymorphisms and stress responsivity. Endocrine 28: 263-270.
43. Zhou, J. & J.A. Cidlowski. 2005. The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids 70: 407-417.
44. Lewis-Tuffin, L.J. & J.A. Cidlowski. 2006. The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance. Ann. N.Y. Acad. Sci. 1069: 1-9.
45. Webster, J.C. et al. 2001. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance. Proc. Natl. Acad. Sci. U.S.A. 98: 6865-6870.
46. Derijk, R.H. et al. 2001. A human glucocorticoid receptor gene variant that increases the stability of the glucocorticoid receptor beta-isoform mRNA is associated with rheumatoid arthritis. J. Rheumatol. 28: 2383-2388.
47. Russcher, H. et al. 2005. Increased expression of the glucocorticoid receptor-A translational isoform as a result of the ER22/23EK polymorphism. Mol. Endocrinol. 19: 1687-1696.
48. Weaver, I.C. et al. 2004. Epigenetic programming by maternal behavior. Nat. Neurosci. 7: 847-854.
49. McGowan, P.O. et al. 2009. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat. Neurosci. 12: 342-38.
50. Marques, A.H., M.N. Silverman & E.M. Sternberg. 2009. Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics. Ann. N.Y. Acad. Sci. 1179: 1-18.
51. Pace, T.W., F. Hu & A.H. Miller. 2007. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav. Immun. 21: 9-19.
52. Tait, A.S. et al. 2007. The large clostridial toxins from Clostridium sordellii and C. difficile repress glucocorticoid receptor activity. Infect. Immun. 75: 3935-3940.
53. Webster, J.I. & E.M. Sternberg. 2005. Anthrax lethal toxin represses glucocorticoid receptor (GR) transactivation by inhibiting GR-DNA binding in vivo. Mol. Cell Endocrinol. 241: 21-31.
54. Webster, J.I. et al. 2003. Anthrax lethal factor represses glucocorticoid and progesterone receptor activity. Proc. Natl. Acad. Sci. U.S.A. 100: 5706-5711.
55. Rohleder, N. 2012. Acute and chronic stress induced changes in sensitivity of peripheral inflammatory pathways to the signals of multiple stress systems-2011 Curt Richter Award Winner. Psychoneuroendocrinology 37: 307-316.
56. Miller, G.E. et al. 2008. A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-kappaB signaling. Biol. Psychiatry 64: 266-272.
57. Miller, G.E., S. Cohen & A.K. Ritchey. 2002. Chronic psychological stress and the regulation of proinflammatory cytokines: a glucocorticoid-resistance model. Health Psychol. 21: 531-541.
58. Avitsur, R. et al. 2009. Social interactions, stress, and immunity. Immunol. Allergy Clin. North Am. 29: 285-293.
59. Hayley, S., Z. Merali & H. Anisman. 2003. Stress and cytokine-elicited neuroendocrine and neurotransmitter sensitization: implications for depressive illness. Stress 6: 19-32.
60. Barden, N. 2004. Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression. J. Psychiatry Neurosci. 29: 185-193.
61. Zunszain, P.A. et al. 2011. Glucocorticoids, cytokines and brain abnormalities in depression. Prog. Neuropsychopharmacol Biol. Psychiatry 35: 722-729.
62. Sternberg, E.M. 2006. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nature Rev. Immunol. 6: 318-328.
63. Straub, R.H. et al. 2010. Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J. Intern. Med. 267: 543-560.
64. Black, P.H. 2003. The inflammatory response is an integral part of the stress response: implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain Behav. Immun. 17: 350-364.
65. Chrousos, G.P. & T. Kino. 2007. Glucocorticoid action networks and complex psychiatric and/or somatic disorders. Stress 10: 213-219.
66. McIntyre, R.S. et al. 2007. Should depressive syndromes be reclassified as "metabolic syndrome type II"? Ann. Clin. Psychiatry 19: 257-264.
67. Miller, A.H., V. Maletic & C.L. Raison. 2009. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65: 732-741.
68. Hart, B.L. 1988. Biological basis of the behavior of sick animals. Neurosci. Biobehav. Rev. 12: 123-137.
69. Capuron, L. et al. 2009. Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals? J. Affect. Disord. 119: 181-185.
70. Goujon, E. et al. 1997. Regulation of cytokine gene expression in the central nervous system by glucocorticoids: mechanisms and functional consequences. Psychoneuroendocrinology 22: S75-S80.
71. Nadeau, S. & S. Rivest. 2003. Glucocorticoids play a fundamental role in protecting the brain during innate immune response. J. Neurosci. 23: 5536-5544.
72. Johnson, R.W., M.J. Propes & Y. Shavit. 1996. Corticosterone modulates behavioral and metabolic effects of lipopolysaccharide. Am. J. Physiol. 270: R192-R198.
73. Pezeshki, G., T. Pohl & B. Schöbitz. 1996. Corticosterone controls interleukin-1 beta expression and sickness behavior in the rat. J. Neuroendocrinol. 8: 129-135.
74. Wang, D. et al. 2011. Chronic blockade of glucocorticoid receptors by RU486 enhances lipopolysaccharide-induced depressive-like behaviour and cytokine production in rats. Brain Behav. Immun. 25: 706-714.
75. Beisel, W.R. 1975. Metabolic response to infection. Annu. Rev. Med. 26: 9-20.
76. Chang, H.R. & B. Bistrian. 1998. The role of cytokines in the catabolic consequences of infection and injury. JPEN J. Parenter. Enteral. Nutr. 22: 156-166.
77. Capuron, L. et al. 2008. Depressive symptoms and metabolic syndrome: is inflammation the underlying link? Biol. Psychiatry 64: 896-900.
78. Clark, A.R. 2007. Anti-inflammatory functions of glucocorticoid-induced genes. Mol. Cell. Endocrinol. 275: 79-97.
79. Schacke, H., W.D. Docke & K. Asadullah. 2002. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 96: 23-43.
80. Reichardt, H.M. et al. 1998. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 93: 531-541.
81. Reichardt, H.M. et al. 2001. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J. 20: 7168-7173.
82. Grose, R. et al. 2002. A role for endogenous glucocorticoids in wound repair. EMBO Rep. 3: 575-582.
83. Tuckermann, J.P. et al. 2007. Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J. Clin. Invest. 117: 1381-1390.
84. Kleiman, A. et al. 2012. Glucocorticoid receptor dimerization is required for survival in septic shock via suppression of interleukin-1 in macrophages. FASEB J. 26: 722-729.
85. De Bosscher, K. et al. 2008. Selective transrepression versus transactivation mechanisms by glucocorticoid receptor modulators in stress and immune systems. Eur. J. Pharmacol. 583: 290-302.
86. Kleiman, A., & J.P. Tuckermann. 2007. Glucocorticoid receptor action in beneficial and side effects of steroid therapy: lessons from conditional knockout mice. Mol. Cell. Endocrinol. 275: 98-108.
87. Marques-Deak, A. et al. 2006. Measurement of cytokines in sweat patches and plasma in healthy women: validation in a controlled study. J. Immunol. Methods 315: 99-109.
88. Cizza, G. et al. 2008. Elevated neuroimmune biomarkers in sweat patches and plasma of premenopausal women with major depressive disorder in remission: the POWER study. Biol. Psychiatry 64: 907-911.
89. Kirschbaum, C. & D.H. Hellhammer. 1994. Salivary cortisol in psychoneuroendocrine research: recent developments and applications. Psychoneuroendocrinology 19: 313-333.
90. Clow, A., F. Hucklebridge & L. Thorn. 2010. The cortisol awakening response in context. Int. Rev. Neurobiol. 93: 153-175.
91. Dettenborn, L. et al. 2012. Introducing a novel method to assess cumulative steroid concentrations: increased hair cortisol concentrations over 6 months in medicated patients with depression. Stress 15: 348-353.
92. Elenkov, I.J. et al. 2000. The sympathetic nerve-an integrative interface between two supersystems: the brain and the immune system. Pharmacol. Rev. 52: 595-638.
93. Nance, D.M. & V.M. Sanders. 2007. Autonomic innervation and regulation of the immune system. Brain Behav. Immun. 21: 736-745.
94. Tracey, K.J. 2007. Physiology and immunology of the cholinergic anti-inflammatory pathway. J. Clin. Invest. 117: 289-296.
95. Thayer, J.F. 2009. Vagal tone and the inflammatory reflex. Cleve. Clin. J. Med. 76: S23-S26.
96. Thayer, J.F. & E. Sternberg. 2006. Beyond heart rate variability: vagal regulation of allostatic systems. Ann. N.Y. Acad. Sci. 1088: 361-372.
97. Nater, U.M. & N. Rohleder. 2009. Salivary alpha-amylase as a non-invasive biomarker for the sympathetic nervous system: current state of research. Psychoneuroendocrinology 34: 486-496.
98. Silverman, M.N., B.D. Pearce & A.H. Miller. 2003. Cytokines and HPA axis regulation. In Cytokines and Mental Health. Z. Kronfol, Ed.: 85-122. Kluwer Adademic Publishers. Norwell, MA.